ACIP

Use of Influenza Vaccines for 2019-20 Season

2019-2020 Seasonal Influenza Recommendations

HPV recommendations.

Updated Recommendations for Human Papillomavirus Vaccination for Adults

Print and mobile-friendly versions of healthcare professionals’ schedules.

Print and mobile-friendly versions of healthcare professionals’ schedules

Contact ACIP Secretariat

1600 Clifton Road, N.E., Mailstop H24-8
Atlanta, GA 30329-4027
acip@cdc.gov

email_03Get Email Updates

To receive email updates about this page, enter your email address:

June 2019 Meeting Recommendations

ACIP approved the following recommendations by majority vote at its June 2019 meeting:

  • Human Papillomavirus (HPV) Vaccine
    • ACIP recommends catch-up vaccination for persons through age 26 years who are not adequately vaccinated
    • ACIP recommends vaccination based on shared clinical decision making for individuals aged 27 through 45 years who are not adequately vaccinated. HPV vaccines are not licensed for use in adults older than age 45 years
  • Pneumococcal Vaccines
    • ACIP recommends PCV13 based on shared clinical decision making for adults 65 years or older who do not have an immunocompromising condition and who have not previously received PCV13. All adults 65 years or older should receive a dose of PPSV23.
  • Influenza Vaccines
    • ACIP recommends annual influenza vaccination is recommended for all persons aged 6 months and older who do not have contraindications.
  • Hepatitis A Vaccines
    • ACIP recommends that all children and adolescents aged 2 through 18 years who have not previously received Hepatitis A vaccine be vaccinated routinely at any age (i.e., children and adolescents are recommended for catch-up vaccination).
    • ACIP recommends all persons with HIV aged ≥1 year be routinely vaccinated with Hepatitis A vaccine.
  • Serogroup B Meningococcal (MenB) Vaccines
    • For persons aged ≥10 years with complement deficiency, complement inhibitor use, asplenia, or who are microbiologists:
      • ACIP recommends a MenB booster dose 1 year following completion of a MenB primary series followed by MenB booster doses every 2-3 years thereafter, for as long as increased risk remains.
    • For persons aged ≥10 years determined by public health officials to be at increased risk during an outbreak:
      • ACIP recommends a one-time booster dose if it has been ≥1 year since completion of a MenB primary series.
      • A booster dose interval of ≥6 months may be considered by public health officials depending on the specific outbreak, vaccination strategy, and projected duration of elevated risk.

These recommendations have been adopted by the CDC Director and will become official once published in MMWR.

Page last reviewed: March 21, 2019